GUTS . Fractyl Health . Q4 2025 Earnings + REMAIN-1 Pivotal Update

Fractyl reported Q4 and full year 2025 results. The stock is at $0.43 with a Nasdaq delisting warning and a September 9 deadline to get back above $1. But the clinical story is actually getting more interesting, not less.

The big news. New post-hoc analyses from the REMAIN-1 Midpoint Cohort show a statistically significant dose-dependent treatment effect for Revita on post-GLP-1 weight maintenance at 6 months (p=0.048). Translation: the longer the duodenal ablation, the better the weight maintenance. That's how drugs work. Dose-response relationships are what the FDA wants to see.

The numbers that matter. In patients with above-median GLP-1 weight loss, Revita reduced post-GLP-1 weight regain by 70% versus sham (p=0.004). The effect widened from 1 to 6 months, meaning it's getting better over time, not fading. In the highest-dose subgroup, Revita patients retained 88% of their GLP-1 weight loss at 6 months versus 60% for sham. That's a real, meaningful difference.

Pivotal cohort is locked and loaded. Randomization complete. Blinded operational data confirms the Pivotal Cohort is sitting in the sweet spot identified by the Midpoint analysis, 16 cm mean ablation length and 18.3% mean total body weight loss at enrollment. Topline 6-month data expected early Q4 2026.

The FDA path. FDA provided pre-submission feedback acknowledging Revita's safety profile is consistent with Class II device classification based on 300+ procedures. De Novo submission targeted late Q4 2026 if pivotal data is positive.

The Rejuva gene therapy platform is a bonus. RJVA-001 for T2D has CTAs submitted in the EU and Australia. First-in-human dosing expected H2 2026. RJVA-002 showed 30% weight loss after a single administration in preclinical obesity models. That's a gene therapy for obesity. Wild.

The financials. $81.5 million cash plus $4.1 million from warrant exercises in January 2026. Runway into early 2027, which gets them past the pivotal data readout. R&D came down to $16.5 million from $20.3 million in Q4 2024. Adjusted EBITDA improved slightly. The $43.7 million net loss includes $20.2 million in non-cash warrant liability adjustments, strip that out and the operating performance actually improved.

The reality check. The stock is at $0.43. Nasdaq delisting deadline is September 9. They need a 133% move to get above $1 or they're doing a reverse split. The pivotal data doesn't read out until Q4 2026, well after the delisting deadline. So either they reverse split to maintain listing, get a partnership announcement, or the Midpoint data generates enough buzz to move the stock organically.

The thesis. 30 million patients projected on GLP-1s by 2035. Most will face discontinuation and weight regain. Fractyl is the only company developing a procedural solution for post-GLP-1 weight maintenance with Breakthrough Device designation. If the pivotal data confirms what the Midpoint showed, this is a massive opportunity. The question is whether the company survives long enough at this stock price to get there.